59717-96-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-bromo-2-phenoxypyridine is used as a building block in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Materials Science:
5-bromo-2-phenoxypyridine is studied for its potential applications in materials science, where its aromatic and heterocyclic nature may contribute to the creation of novel materials with specific properties.
Used as a Ligand in Coordination Chemistry:
5-bromo-2-phenoxypyridine is also considered as a ligand in coordination chemistry, where it can form complexes with metal ions, potentially leading to new catalysts or materials with unique properties.

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 108-95-2 phenol 
• 766-11-0 5-bromo-2-fluoropyridine 

Downstream Products

• 595576-42-4 2-phenoxy-5-thiophen-2-ylpyridine 
• 595576-33-3 5-butyl-2-phenoxypyridine 
• 595576-34-4 5-pentyl-2-phenoxypyridine 
• 595576-31-1 5-ethyl-2-phenoxypyridine 
• 595576-41-3 2-phenoxy-5-phenylpyridine 
• 99902-72-4 5-cyano-2-phenoxypyridine 
• 595576-32-2 2-phenoxy-5-propylpyridine 
• 595576-28-6 3-(6-phenoxypyridin-3-yl)acrylic acid methyl ester 
• 330792-76-2 2-phenoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine 
• 1270921-80-6 (6-phenoxypyridin-3-yl)boronic acid 

Relevant academic research and scientific papers

Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma

Ibrutinib (IBN), a first-in-class BTK-inhibitor, was approved by the FDA for the treatment of mantle cell lymphoma (MCL). Although IBN shows excellent performance as an anti-lymphoma agent, it has some undesirable side effects due to its off-target activities. Our studies yielded a novel series of 3-(6-phenoxypyridin-3-yl)-4-amine-1H-pyrazolo[3,4-d]pyrimidine derivatives capable of potent inhibition of Bruton's tyrosine kinase (BTK). Notably, compound 13e explained potent BTK inhibitory activity and could completely inhibit the phosphorylation of BTK and PLCγ2 in Z138 cells at low micromolar concentration. Compared with IBN, compound 13e improved anti-proliferative activities 3–40 folds in MCL cell lines with IC50 values lower than 1 μM. Low micromolar doses of 13e could induce strong cell apoptosis in Jeko-1 and Z138 cells. In addition, compound 13e showed greater BTK selectivity and higher stability in human liver microsomes than IBN and potential safety improvement for the treatment of MCL.

Reversible covalent Bruton's tyrosine kinase inhibitor, pharmaceutical composition and application thereof

The invention discloses a reversible covalent Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition and application of the compound and the pharmaceutical composition in preparation of drugs for treating diseases, disorders or symptoms benefitting from inhibition of Bruton's tyrosine kinase activity. The compound provided by the invention has strong in-vitro BTK kinase inhibition activity, and can be applied to treatment of diseases, disorders or symptoms, including B-cell lymphoma, autoimmune diseases, inflammatory diseases and the like, which benefit from inhibitionof Bruton's tyrosine kinase activity, alone or in combination with other drugs.

1, 3-di-substituted-4-amino pyrazolopyrimidine compound, preparation method thereof and application of compound

The invention relates to a 1, 3-di-substituted-4-amino pyrazolopyrimidine compound, a preparation method thereof and an application of the compound. The compound is provided with a structure as shownin a formula I. The invention further relates to a preparation method of the compound with the structure as shown in the formula I and a medicine composition. The invention further provides an application of the compound and pharmaceutically acceptable salt thereof to preparation of MCL (mantle cell lymphoma) resistance medicines.

Selective Bruton's tyrosine kinase inhibitor and application thereof

The invention discloses a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, preparation and application thereof to preparation of medicines for treating diseases, disorders or symptoms obtained from inhibition of Bruton's tyrosine kinase activity. The compound disclosed by the invention has anti-proliferation and inhibition effects on tumor cell lines including A549, MINO, OCI-LY10, TMD-8 and the like, has good anti-tumor activity in tumor models including Mino subcutaneous xenoplastic transplantation and the like and can be applied to medicines for treating solid tumors or leukemia related to human or animal cell proliferation; the compound disclosed by the invention has relatively good pharmacokinetic performance and can be orally taken to treat the solid tumors or the leukemia related to the human or animal cell proliferation or autoimmune diseases; the compound disclosed by the invention has a low hERG channel blocking property.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Bruton's tyrosine kinase inhibitor intermediates and preparation method thereof

The invention relates to Bruton's tyrosine kinase inhibitor intermediates which are compounds shown in I, II, III, IV and IV or their pharmaceutically acceptable salt, and structural formulas of I, II, III, IV and V are shown as below. The novel Bruton's tyrosine kinase inhibitor intermediates are provided, a preparation method of these intermediates is convenient and efficient and is helpful for the preparation of novel BTK inhibitors and deep research and even marketing thereof.

PURINONE COMPOUNDS AS KINASE INHIBITORS

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: Study of 6-substituted pyridine-3-boronic acid derivatives

In response to the extensive use of antibiotics, bacteria have evolved numerous mechanisms of defense against antimicrobial agents. Among them, extrusion of the antimicrobial agents outside the bacterial cell through efflux pumps is a major cause of concern. At first limited to one or few structurally-related antibiotics, bacterial resistance have then progressed towards cross-resistance between different classes of antibiotics, leading to multidrug-resistant microorganisms. Emergence of these pathogens requires development of novel therapeutic strategies and inhibition of efflux pumps appears to be a promising strategy that could restore the potency of existing antibiotics. NorA is the most studied chromosomal efflux pump of Staphylococcus aureus; it is known to be implied in resistance of Methicillin-resistant S. aureus (MRSA) strains against a wide range of unrelated substrates, including hydrophilic fluoroquinolones. Starting from 6-benzyloxypyridine-3-boronic acid I that we previously identified as a potential inhibitor of the NorA efflux pump against the NorA-overexpressing S. aureus 1199B strain (SA1199B), we describe here the synthesis and biological evaluation of a series of 6-(aryl)alkoxypyridine-3-boronic acids. 6-(3-Phenylpropoxy)pyridine-3-boronic acid 3i and 6-(4-phenylbutoxy)pyridine-3-boronic acid 3j were found to potentiate ciprofloxacin activity by a 4-fold increase compared to the parent compound I. In addition, it has been shown that both compounds promote Ethidium Bromide (EtBr) accumulation in SA1199B, thus corroborating their potential mode of action as NorA inhibitors.

Copper-catalyzed highly regioselective 2-aryloxylation of 2,x-dihalopyridines

2,x-Dihalopyridines reacted with phenols catalyzed by CuI/TMEDA in the presence of Cs2CO3 in DMSO at 110 °C under nitrogen atmosphere for 24 h to afford 2-aryloxypyridines in good to high yields except p-nitrophenol. To expand this methodology, a vanilloid receptor ligand used in treatments was prepared in good yield. This method has potential utility in the synthesis of pharmaceuticals, agrochemicals and even natural products.